Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
A2RUC4
UPID:
TYW5_HUMAN
Alternative names:
tRNA(Phe) (7-(3-amino-3-carboxypropyl)wyosine(37)-C(2))-hydroxylase
Alternative UPACC:
A2RUC4; B2RNE3; Q8N1R2
Background:
The tRNA wybutosine-synthesizing protein 5 plays a crucial role in the wybutosine biosynthesis pathway, essential for the modification of phenylalanine tRNA in eukaryotes. It specifically catalyzes the hydroxylation of yW-72, leading to the production of hydroxywybutosine, a key component in protein synthesis.
Therapeutic significance:
Understanding the role of tRNA wybutosine-synthesizing protein 5 could open doors to potential therapeutic strategies.